Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan/Aliskiren vs Valsartan in Stage 2 Hypertension
NCT00809926Phase 4Completed
- Sponsor
- Novartis
- Start
- Jan 2009
- Primary completion
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aliskiren in hypertension (HTN) (2 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Mean Sitting Systolic Blood Pressure at 8 weeks. Started Jan 2009; status: completed.
02
Drugs
aliskiren
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00809926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00809926.